Limited activity in CDK4- or CDK6-amplified tumors, although central nervous system tumors warrant future investigation from this phase II trial of palbociclib in cancer patients. Results from NCI-MATCH ECOG-ACRIN Trial EAY131 Subprotocol Z1C @uofpenn.bsky.social https://aacrjournals.org/clincancerres/article-abstract/doi/10.1158/1078-0432.CCR-24-0036/750383/Phase-II-Study-of-Palbociclib-in-Patients-with